Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical Reviews in Allergy & Immunology
Published in: Clinical Reviews in Allergy & Immunology 2/2011

01-04-2011

A Contemporary Update on Scleroderma

Author: Loïc Guillevin

Published in: Clinical Reviews in Allergy & Immunology | Issue 2/2011

Login to get access

Excerpt

Systemic sclerosis is a rare disease which remains, by many aspects, an enigma and a therapeutic challenge for physicians. It is one of the last “autoimmune” diseases to have a poor prognosis and respond poorly to treatments. The treatment of scleroderma has been very problematic for a number of reasons. Firstly, the genetic basis, although intensely studied, remains unclear and there are no definitive genome-wide association studies published. Second, the pathogenesis of systemic sclerosis is complex, associating several mechanisms including endothelial dysfunction, fibrosis, autoimmunity, and allo-reactivity. Further, all these mechanisms may be inter-related and may change during the disease course. Hence, therapy is a challenge. Further, should therapy focus entirely on specific organ involvement or will there be specific drugs that will modulate the course of disease? Will there ever be drugs that target the complexity of mechanisms present at each disease stage? …
Literature
1.
Aggarwal R, Lucas M, Fertig N, Oddis CV, Medsger TA Jr (2009) Anti-U3 RNP autoantibodies in systemic sclerosis. Arthritis Rheum 60:1112–1118CrossRefPubMed
2.
Akhmetshina A, Venalis P, Dees C, Busch N, Zwerina J, Schett G, Distler O, Distler JH (2009) Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum 60:219–224CrossRefPubMed
3.
Alonso N, Soldevila B, Sanmarti A, Pujol-Borrell R, Martinez-Caceres E (2009) Regulatory T cells in diabetes and gastritis. Autoimmun Rev 8:659–662CrossRefPubMed
4.
Amjadi S, Maranian P, Furst DE, Clements PJ, Wong WK, Postlethwaite AE, Khanna PP, Khanna D (2009) Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials. Arthritis Rheum 60:2490–2498CrossRefPubMed
5.
Askenasy N, Kaminitz A, Yarkoni S (2008) Mechanisms of T regulatory cell function. Autoimmun Rev 7:370–375CrossRefPubMed
6.
Beretta L, Cappiello F, Moore JH, Barili M, Greene CS, Scorza R (2008) Ability of epistatic interactions of cytokine single-nucleotide polymorphisms to predict susceptibility to disease subsets in systemic sclerosis patients. Arthritis Rheum 59:974–983CrossRefPubMed
7.
Bernatsky S, Hudson M, Panopalis P, Clarke AE, Pope J, Leclercq S, St Pierre Y, Baron M (2009) The cost of systemic sclerosis. Arthritis Rheum 61:119–123PubMed
8.
Bernatsky S, Hudson M, Pope J, Vinet E, Markland J, Robinson D, Jones N, Docherty P, Abu-Hakima M, Leclercq S, Dunne J, Smith D, Mathieu JP, Khalidi N, Sutton E, Baron M (2008) Assessment of reproductive history in systemic sclerosis. Arthritis Rheum 59:1661–1664CrossRefPubMed
9.
Bernatsky S, Joseph L, Pineau CA, Belisle P, Hudson M, Clarke AE (2009) Scleroderma prevalence: demographic variations in a population-based sample. Arthritis Rheum 61:400–404CrossRefPubMed
10.
Bianco NR, Kim SH, Ruffner MA, Robbins PD (2009) Therapeutic effect of exosomes from indoleamine 2, 3-dioxygenase-positive dendritic cells in collagen-induced arthritis and delayed-type hypersensitivity disease models. Arthritis Rheum 60:380–389CrossRefPubMed
11.
Bogatkevich GS, Ludwicka-Bradley A, Silver RM (2009) Dabigatran, a direct thrombin inhibitor, demonstrates antifibrotic effects on lung fibroblasts. Arthritis Rheum 60:3455–3464CrossRefPubMed
12.
Campbell IK, Kinkel SA, Drake SF, van Nieuwenhuijze A, Hubert FX, Tarlinton DM, Heath WR, Scott HS, Wicks IP (2009) Autoimmune regulator controls T cell help for pathogenetic autoantibody production in collagen-induced arthritis. Arthritis Rheum 60:1683–1693CrossRefPubMed
13.
14.
15.
Chiorini JA, Cihakova D, Ouellette CE, Caturegli P (2009) Sjogren syndrome: advances in the pathogenesis from animal models. J Autoimmun 33:190–196CrossRefPubMed
16.
Christen U, Hintermann E, Holdener M, von Herrath MG (2010) Viral triggers for autoimmunity: is the 'glass of molecular mimicry' half full or half empty? J Autoimmun 34(1):38–44CrossRefPubMed
17.
Chung L, Fiorentino DF, Benbarak MJ, Adler AS, Mariano MM, Paniagua RT, Milano A, Connolly MK, Ratiner BD, Wiskocil RL, Whitfield ML, Chang HY, Robinson WH (2009) Molecular framework for response to imatinib mesylate in systemic sclerosis. Arthritis Rheum 60:584–591CrossRefPubMed
18.
19.
Dhirapong A, Lleo A, Leung P, Gershwin ME, Liu FT (2009) The immunological potential of galectin-1 and -3. Autoimmun Rev 8:360–363CrossRefPubMed
20.
Dieude P, Wipff J, Guedj M, Ruiz B, Melchers I, Hachulla E, Riemekasten G, Diot E, Hunzelmann N, Sibilia J, Tiev K, Mouthon L, Cracowski JL, Carpentier PH, Distler J, Amoura Z, Tarner I, Avouac J, Meyer O, Kahan A, Boileau C, Allanore Y (2009) BANK1 is a genetic risk factor for diffuse cutaneous systemic sclerosis and has additive effects with IRF5 and STAT4. Arthritis Rheum 60:3447–3454CrossRefPubMed
21.
Distler JH, Beyer C, Schett G, Luscher TF, Gay S, Distler O (2009) Endothelial progenitor cells: novel players in the pathogenesis of rheumatic diseases. Arthritis Rheum 60:3168–3179CrossRefPubMed
22.
Doria A, Canova M, Tonon M, Zen M, Rampudda E, Bassi N, Atzeni F, Zampieri S, Ghirardello A (2008) Infections as triggers and complications of systemic lupus erythematosus. Autoimmun Rev 8:24–28CrossRefPubMed
23.
Elagin RB, Balijepalli S, Diacovo MJ, Baekkeskov S, Jaume JC (2009) Homing of GAD65 specific autoimmunity and development of insulitis requires expression of both DQ8 and human GAD65 in transgenic mice. J Autoimmun 33:50–57CrossRefPubMed
24.
Fiocco U, Sfriso P, Oliviero F, Pagnin E, Scagliori E, Campana C, Dainese S, Cozzi L, Punzi L (2008) Co-stimulatory modulation in rheumatoid arthritis: the role of (CTLA4-Ig) abatacept. Autoimmun Rev 8:76–82CrossRefPubMed
25.
Fuschiotti P, Medsger TA Jr, Morel PA (2009) Effector CD8+ T cells in systemic sclerosis patients produce abnormally high levels of interleukin-13 associated with increased skin fibrosis. Arthritis Rheum 60:1119–1128CrossRefPubMed
26.
Gleicher N, Elkayam U (2009) Peripartum cardiomyopathy, an autoimmune manifestation of allograft rejection? Autoimmun Rev 8:384–387CrossRefPubMed
27.
Gomez-Martin D, Diaz-Zamudio M, Alcocer-Varela J (2008) Ubiquitination system and autoimmunity: the bridge towards the modulation of the immune response. Autoimmun Rev 7:284–290PubMed
28.
Gonzalez MA, Gonzalez-Rey E, Rico L, Buscher D, Delgado M (2009) Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells. Arthritis Rheum 60:1006–1019CrossRefPubMed
29.
Guiducci S, Distler JH, Jungel A, Huscher D, Huber LC, Michel BA, Gay RE, Pisetsky DS, Gay S, Matucci-Cerinic M, Distler O (2008) The relationship between plasma microparticles and disease manifestations in patients with systemic sclerosis. Arthritis Rheum 58:2845–2853CrossRefPubMed
30.
Harrison LC, Honeyman MC, Morahan G, Wentworth JM, Elkassaby S, Colman PG, Fourlanos S (2008) Type 1 diabetes: lessons for other autoimmune diseases? J Autoimmun 31:306–310CrossRefPubMed
31.
Hasegawa M, Matsushita Y, Horikawa M, Higashi K, Tomigahara Y, Kaneko H, Shirasaki F, Fujimoto M, Takehara K, Sato S (2009) A novel inhibitor of Smad-dependent transcriptional activation suppresses tissue fibrosis in mouse models of systemic sclerosis. Arthritis Rheum 60:3465–3475CrossRefPubMed
32.
Hemminki K, Li X, Sundquist J, Sundquist K (2009) The epidemiology of Graves' disease: Evidence of a genetic and an environmental contribution. J Autoimmun (in press)
33.
Hewagama A, Richardson B (2009) The genetics and epigenetics of autoimmune diseases. J Autoimmun 33:3–11CrossRefPubMed
34.
Hoffmann MH, Trembleau S, Muller S, Steiner G (2009) Nucleic acid-associated autoantigens: pathogenic involvement and therapeutic potential. J Autoimmun
35.
Holz LE, Warren A, Le Couteur DG, Bowen DG, Bertolino P (2010) CD8+ T cell tolerance following antigen recognition on hepatocytes. J Autoimmun 34(1):15–22CrossRefPubMed
36.
Hudson M, Rojas-Villarraga A, Coral-Alvarado P, Lopez-Guzman S, Mantilla RD, Chalem P, Baron M, Anaya JM (2008) Polyautoimmunity and familial autoimmunity in systemic sclerosis. J Autoimmun 31:156–159CrossRefPubMed
37.
Hudson M, Thombs B, Baron M (2009) Time to diagnosis in systemic sclerosis: is sex a factor? Arthritis Rheum 61:274–278CrossRefPubMed
38.
Hudson M, Thombs BD, Steele R, Panopalis P, Newton E, Baron M (2009) Health-related quality of life in systemic sclerosis: a systematic review. Arthritis Rheum 61:1112–1120CrossRefPubMed
39.
Jamin C, Morva A, Lemoine S, Daridon C, de Mendoza AR, Youinou P (2008) Regulatory B lymphocytes in humans: a potential role in autoimmunity. Arthritis Rheum 58:1900–1906CrossRefPubMed
40.
Kabalak G, Dobberstein SB, Matthias T, Reuter S, The YH, Dorner T, Schmidt RE, Witte T (2009) Association of immunoglobulin-like transcript 6 deficiency with Sjogren's syndrome. Arthritis Rheum 60:2923–2925CrossRefPubMed
41.
Kaminitz A, Mizrahi K, Yaniv I, Farkas DL, Stein J, Askenasy N (2009) Low levels of allogeneic but not syngeneic hematopoietic chimerism reverse autoimmune insulitis in prediabetic NOD mice. J Autoimmun 33:83–91CrossRefPubMed
42.
Kong YC, Morris GP, Brown NK, Yan Y, Flynn JC, David CS (2009) Autoimmune thyroiditis: a model uniquely suited to probe regulatory T cell function. J Autoimmun 33:239–246CrossRefPubMed
43.
La Cava A (2008) Tregs are regulated by cytokines: implications for autoimmunity. Autoimmun Rev 8:83–87CrossRefPubMed
44.
Lafyatis R, Kissin E, York M, Farina G, Viger K, Fritzler MJ, Merkel PA, Simms RW (2009) B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 60:578–583CrossRefPubMed
45.
Leuschner F, Katus HA, Kaya Z (2009) Autoimmune myocarditis: past, present and future. J Autoimmun 33:282–289CrossRefPubMed
46.
Li DH, Winslow MM, Cao TM, Chen AH, Davis CR, Mellins ED, Utz PJ, Crabtree GR, Parnes JR (2008) Modulation of peripheral B cell tolerance by CD72 in a murine model. Arthritis Rheum 58:3192–3204CrossRefPubMed
47.
Lleo A, Invernizzi P, Gao B, Podda M, and Gershwin ME (2009) Definition of human autoimmunity—autoantibodies versus autoimmune disease. Autoimmun Rev
48.
Loizos N, Lariccia L, Weiner J, Griffith H, Boin F, Hummers L, Wigley F, Kussie P (2009) Lack of detection of agonist activity by antibodies to platelet-derived growth factor receptor alpha in a subset of normal and systemic sclerosis patient sera. Arthritis Rheum 60:1145–1151CrossRefPubMed
49.
Mathai SC, Hummers LK, Champion HC, Wigley FM, Zaiman A, Hassoun PM, Girgis RE (2009) Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. Arthritis Rheum 60:569–577CrossRefPubMed
50.
Meune C, Avouac J, Wahbi K, Cabanes L, Wipff J, Mouthon L, Guillevin L, Kahan A, Allanore Y (2008) Cardiac involvement in systemic sclerosis assessed by tissue-doppler echocardiography during routine care: A controlled study of 100 consecutive patients. Arthritis Rheum 58:1803–1809CrossRefPubMed
51.
Meyer-Bahlburg A, Rawlings DJ (2008) B cell autonomous TLR signaling and autoimmunity. Autoimmun Rev 7:313–316CrossRefPubMed
52.
Midgley A, McLaren Z, Moots RJ, Edwards SW, Beresford MW (2009) The role of neutrophil apoptosis in juvenile-onset systemic lupus erythematosus. Arthritis Rheum 60:2390–2401CrossRefPubMed
53.
Morohoshi K, Goodwin AM, Ohbayashi M, Ono SJ (2009) Autoimmunity in retinal degeneration: autoimmune retinopathy and age-related macular degeneration. J Autoimmun 33:247–254CrossRefPubMed
54.
Morris GP, Brown NK, Kong YC (2009) Naturally existing CD4(+)CD25(+)Foxp3(+) regulatory T cells are required for tolerance to experimental autoimmune thyroiditis induced by either exogenous or endogenous autoantigen. J Autoimmun 33:68–76CrossRefPubMed
55.
Mouthon L, Rannou F, Berezne A, Pagnoux C, Guilpain P, Goldwasser F, Revel M, Guillevin L, Fermanian J, Poiraudeau S (2008) Patient preference disability questionnaire in systemic sclerosis: a cross-sectional survey. Arthritis Rheum 59:968–973CrossRefPubMed
56.
Peron JP, de Oliveira AP, Rizzo LV (2009) It takes guts for tolerance: the phenomenon of oral tolerance and the regulation of autoimmune response. Autoimmun Rev 9:1–4CrossRefPubMed
57.
Pessach IM, Notarangelo LD (2009) X-linked primary immunodeficiencies as a bridge to better understanding X chromosome-related autoimmunity. J Autoimmun 33:17–24CrossRefPubMed
58.
Picha L, Pakas I, Guialis A, Moutsopoulos HM, Vlachoyiannopoulos PG (2008) Comparative qualitative and quantitative analysis of scleroderma (systemic sclerosis) serologic immunoassays. J Autoimmun 31:166–174CrossRefPubMed
59.
Razykov I, Thombs BD, Hudson M, Bassel M, Baron M (2009) Prevalence and clinical correlates of pruritus in patients with systemic sclerosis. Arthritis Rheum 61:1765–1770CrossRefPubMed
60.
Robitaille G, Christin MS, Clement I, Senecal JL, Raymond Y (2009) Nuclear autoantigen CENP-B transactivation of the epidermal growth factor receptor via chemokine receptor 3 in vascular smooth muscle cells. Arthritis Rheum 60:2805–2816CrossRefPubMed
61.
Round JL, O'Connell RM, and Mazmanian SK (2009) Coordination of tolerogenic immune responses by the commensal microbiota. J Autoimmun (in press)
62.
Saha S, Gonzalez J, Rosenfeld G, Keiser H, Peeva E (2009) Prolactin alters the mechanisms of B cell tolerance induction. Arthritis Rheum 60:1743–1752CrossRefPubMed
63.
Scaglione BJ, Salerno E, Gala K, Pan M, Langer JA, Mostowski HS, Bauer S, Marti G, Li Y, Tsiagbe VK, Raveche ES (2009) Regulatory T cells as central regulators of both autoimmunity and B cell malignancy in New Zealand Black mice. J Autoimmun 32:14–23CrossRefPubMed
64.
Schouffoer AA, van der Marel J, Ter Kuile MM, Weijenborg PT, Voskuyl A, Vliet Vlieland CW, van Laar JM, Vliet Vlieland TP (2009) Impaired sexual function in women with systemic sclerosis: a cross-sectional study. Arthritis Rheum 61:1601–1608CrossRefPubMed
65.
Schulze C, Munoz LE, Franz S, Sarter K, Chaurio RA, Gaipl US, Herrmann M (2008) Clearance deficiency—a potential link between infections and autoimmunity. Autoimmun Rev 8:5–8CrossRefPubMed
66.
Su TI, Khanna D, Furst DE, Danovitch G, Burger C, Maranian P, Clements PJ (2009) Rapamycin versus methotrexate in early diffuse systemic sclerosis: results from a randomized, single-blind pilot study. Arthritis Rheum 60:3821–3830CrossRefPubMed
67.
Subleski JJ, Wiltrout RH, Weiss JM (2009) Application of tissue-specific NK and NKT cell activity for tumor immunotherapy. J Autoimmun 33:275–281CrossRefPubMed
68.
Szekanecz E, Szucs G, Szekanecz Z, Tarr T, Antal-Szalmas P, Szamosi S, Szanto J, Kiss E (2008) Tumor-associated antigens in systemic sclerosis and systemic lupus erythematosus: associations with organ manifestations, immunolaboratory markers and disease activity indices. J Autoimmun 31:372–376CrossRefPubMed
69.
70.
Villela R, Yuen SY, Pope JE, Baron M (2008) Assessment of unmet needs and the lack of generalizability in the design of randomized controlled trials for scleroderma treatment. Arthritis Rheum 59:706–713CrossRefPubMed
71.
Waldner H (2009) The role of innate immune responses in autoimmune disease development. Autoimmun Rev 8:400–404CrossRefPubMed
72.
Yaniv I, Ash S, Farkas DL, Askenasy N, Stein J (2009) Consideration of strategies for hematopoietic cell transplantation. J Autoimmun 33:255–259CrossRefPubMed
73.
Youinou P, Jamin C (2009) The weight of interleukin-6 in B cell-related autoimmune disorders. J Autoimmun 32:206–210CrossRefPubMed
74.
Zhang J, Jacobi AM, Wang T, Berlin R, Volpe BT, Diamond B (2009) Polyreactive autoantibodies in systemic lupus erythematosus have pathogenic potential. J Autoimmun 33:270–274CrossRefPubMed
Metadata
Title
A Contemporary Update on Scleroderma
Author
Loïc Guillevin
Publication date
01-04-2011
Publisher
Humana Press Inc
Published in
Clinical Reviews in Allergy & Immunology / Issue 2/2011
Print ISSN: 1080-0549
Electronic ISSN: 1559-0267
DOI
https://doi.org/10.1007/s12016-010-8200-8

Other articles of this Issue 2/2011

Clinical Reviews in Allergy & Immunology 2/2011 Go to the issue

OriginalPaper

Scleroderma Renal Crisis: A Rare but Severe Complication of Systemic Sclerosis

OriginalPaper

The Pathogenesis of Systemic Sclerosis Revisited

ReviewPaper

Diagnosis and Classification of Systemic Sclerosis

OriginalPaper

Scleroderma Lung Disease

OriginalPaper

Idiopathic Pulmonary Fibrosis—an Epidemiological and Pathological Review
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits